ArticleJournal of inflammation research2025
ITGB7 Remodels Inflammation and Immune Microenvironment and Enhances Checkpoint Inhibitor-Based Immunotherapy in Pancreatic Cancer.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of ITGB7 in pancreatic ductal adenocarcinoma (PDAC) remains unreported. This study aims to investigate the effects of ITGB7 on inflammation and immune microenvironment, and its correlation with the response to immune checkpoint inhibitors (ICIs). Methods: The correlation between ITGB7 expression and the response to ICIs treatment was evaluated in our clinical cohort and in the TCGA dataset. TMT and PRM proteomic analysis identified ITGB7-associated proteins, biological processes, and signal pathways. The role of ITGB7 in macrophage polarization was explored both in vivo and in vitro. Additionally, ITGB7-associated immune and inflammatory regulatory molecules, and immune cells infiltration in PDAC were assessed using TCGA dataset. An ITGB7-associated ceRNA network was constructed to explore post-transcriptional regulation. Results: Clinical sample analysis and TCGA analysis showed that ITGB7 was significantly overexpressed in PDAC compared to normal pancreatic tissue. Patients with high ITGB7 expression demonstrated a better response to ICIs blockade therapy and exhibited a favorable prognosis. Proteomic analysis indicated that ITGB7 regulates immune- and inflammation- related proteins. ITGB7 expressed in pancreatic tumor cells promoted M2 macrophage polarization. ITGB7 modulated immune-related signaling pathways and was positively correlated with expression of immune checkpoint molecules, inflammatory cytokines, and immune-stimulating molecules. ITGB7 correlated with increased immune cell infiltration. Conclusion: We provide the first evidence that ITGB7 expression correlates with immune regulation, inflammatory modulation, and immune cell infiltration in PDAC. ITGB7 is associated with enhanced immunotherapy response and improved prognosis. This study provides novel insights into the regulation of PDAC immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.